Biomarck is developing technology that utilizes targeted anti-MARCKS technology for the treatment of Cancer, Acute Respiratory Distress Syndrome (ARDS), and hard to treat diseases
Proud to be recognized for 2019 “30 Best Companies of the year” CIO Bulletin and 2018 Winner” and Best Pipeline of Promise”, BIO 2018
BIO-11006 Demonstrated Safety and a 43 Percent Reduction in all-Cause Mortality at 28 Days in ARDS
PressBiomarck is a biopharmaceutical company focused on the development of drugs to treat ARDS, COPD, cancer and other hard to treat diseases. With over 100 patented peptides in our global portfolio, we utilize anti-MARCKS proteins to selectively inhibit cancer progression and the inflammatory cytokine release involved in respiratory diseases and other severe illnesses. We are dedicated to developing safe and targeted treatments for patients in need with our platform technology.
Professor Kenneth Adler was the first to inhibit the biological function of the MARCKS protein from his lab at North Carolina Sate University. Dr. Adler has published over 120 papers, mostly in the areas of airway inflammation, mucus secretion and cancer. He is an inventor or co-inventor on 51 patents. Understanding the method of action (MOA) related to inhibiting MARCKS protein is how Biomarck’s peptides are developed for the treatment of different diseases.
